Claims for Patent: 8,802,714

Summary for Patent: 8,802,714

Title:	Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Abstract:	Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Inventor(s):	Jordan; Robert F. (Corvallis, OR), Bailey; Thomas R. (Phoenixville, PA), Rippin; Susan R. (Wilmington, DE), Dai; Dongcheng (Corvallis, OR)
Assignee:	Siga Technologies, Inc. (Corvallis, OR)
Application Number:	13/966,392
Patent Claims:	1. A method of treating or preventing an infection caused by an orthopox virus in a living host having or susceptible to said infection, said method comprising administering to said living host a therapeutically effective amount of a mixture of compounds comprising: (a) N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-et- henocycloprop [f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide; and (b) N-[(3aR,4S,4aS,5aR,6R,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-et- henocycloprop [f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein said mixture comprises at least about 95% by weight of N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-et- henocycloprop [f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide. 3. The method of claim 1, wherein said mixture comprises no more than about 5% by weight of N-[(3aR,4S,4aS,5aR,6R,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-Et- henocycloprop [f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide. 4. The method of claim 1, wherein said mixture consists of: (a) about 98.5% by weight of N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-et- henocycloprop [f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide; and (b) about 1.5% of N-[(3aR,4S,4aS,5aR,6R,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-et- henocycloprop [f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide. 5. The method of claim 1, wherein said living host is a mammal. 6. The method of claim 1, wherein said living host is a human. 7. The method of claim 1, wherein the orthopox virus is selected from the group consisting of aractuba virus, BeAn 58058 virus, buffalopox virus, camelpox virus, cantagalo orthopoxvirus, cowpox virus, Ectromelia virus, elephantpox virus, monkeypox virus, rabbitpox virus, raccoonpox virus, skunkpox virus, taterapox virus, vaccinia virus, smallpox virus, and volepox virus. 8. The method of claim 7, wherein the orthopox virus is selected from the group consisting of vaccinia virus, cowpox virus, smallpox virus, monkeypox virus and camelpox virus. 9. The method of claim 1, wherein said mixture of compounds is administered in unit dosage form containing about 0.125 to about 250 mg of said compound per kilogram of patient body weight per day. 10. The method of claim 9, wherein said unit dosage includes a pharmaceutically acceptable carrier medium. 11. The method of claim 1, wherein said mixture of compounds is administered in combination with at least one supplemental active agent selected from the group consisting of interferons, ribavirin, immunoglobulins, immunomodulators, anti-inflammatory agents, antibiotics, antivirals or anti-infectious agents. 12. The method of claim 11, wherein said mixture of compounds and said at least one supplemental active agent are administered simultaneously. 13. The method of claim 1, wherein said route of administration is selected from the group consisting of orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, locally or by inhalation. 14. The method of claim 1, wherein said orthopox virus is an attenuated strain of vaccinia virus. 15. The method of claim 14, wherein said attenuated strain provides protective immunity against variola virus.